Mirella Pastore1
Stefania Grimaudo2
Rosaria Maria Pipitone2
Giulia Lori1
Chiara Raggi1,3*
Salvatore Petta2
Fabio Marra1*- 1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- 2Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy
- 3Humanitas Clinical and Research Center, Rozzano, Italy
Recent lines of evidence highlight the involvement of myeloid-epithelial-reproductive tyrosine kinase (MerTK) in metabolic disease associated with liver damage. MerTK is mainly expressed in anti-inflammatory M2 macrophages where it mediates transcriptional changes including suppression of proinflammatory cytokines and enhancement of inflammatory repressors. MerTK is regulated by metabolic pathways through nuclear sensors including LXRs, PPARs, and RXRs, in response to apoptotic bodies or to other sources of cholesterol. Nonalcoholic fatty liver disease (NAFLD) is one of the most serious public health problems worldwide. It is a clinicopathological syndrome closely related to obesity, insulin resistance, and oxidative stress. It includes a spectrum of conditions ranging from simple steatosis, characterized by hepatic fat accumulation with or without inflammation, to nonalcoholic steatohepatitis (NASH), defined by hepatic fat deposition with hepatocellular damage, inflammation, and accumulating fibrosis. Several studies support an association between NAFLD and the incidence of cardiovascular diseases including atherosclerosis, a major cause of death worldwide. This pathological condition consists in a chronic and progressive inflammatory process in the intimal layer of large- and medium-sized arteries. The complications of advanced atherosclerosis include chronic or acute ischemic damage in the tissue perfused by the affected artery, leading to cellular death. By identifying specific targets influencing lipid metabolism and cardiovascular-related diseases, the present review highlights the role of MerTK in NAFLD-associated atherosclerotic lesions as a potential innovative therapeutic target. Therapeutic advantages might derive from the use of compounds selective for nuclear receptors targeting PPARs rather than LXRs regulating macrophage lipid metabolism and macrophage mediated inflammation, by favoring the expression of MerTK, which mediates an immunoregulatory action with a reduction in inflammation and in atherosclerosis.
Metabolic Aspects of NAFLD: Insulin Resistance, Metabolic Syndrome, and Type 2 Diabetes
Nonalcoholic liver disease (NAFLD) was firstly described in 1980 (Ludwig et al., 1980) and is currently the most common cause of chronic liver disease worldwide (Li et al., 2018). The global prevalence of NAFLD is estimated to be approximately 25%, with the highest rates in South America (31%) and Middle East (32%), followed by Asia (27%), USA (24%), Europe (23%), and Africa (14%) (Younossi et al., 2016). NAFLD comprises a spectrum of conditions ranging from simple hepatic lipid accumulation without inflammation, defined nonalcoholic fatty liver or NAFL, to nonalcoholic steatohepatitis (NASH), characterized by hepatic fat deposition with hepatocellular damage, inflammation, and fibrosis. This latter form in a smaller proportion of patients may lead to a series of complications including cirrhosis, liver failure, and hepatocellular carcinoma (HCC) (Marra et al., 2008; Ofosu et al., 2018). Cirrhosis may develop after about 15–20 years of chronic hepatocellular damage, and it is mainly characterized by a modified deposition of extracellular matrix components that, in cirrhotic liver, can be up to six times higher than in normal liver (Parola and Pinzani, 2018). In addition, inflammatory response contributes to hepatic encephalopathy, portal hypertension, liver failure, and increased risk of HCC (Tacke and Trautwein, 2015).
The development and progression of NAFLD is a complex and multifactorial process. NAFLD pathogenesis was originally described by the “two-hits hypothesis” (Day and James, 1998). According to this assumption, the “first hit” is represented by an excess intrahepatic lipid accumulation due to high intake of saturated fats, obesity, IR, and excessive fatty acids in the circulation (Marra, 2004). This sensitizes the liver to further insults acting as a “second hit” (Del Campo et al., 2018) including oxidative stress, lipid peroxidation, and mitochondrial dysfunction. These events give rise to a lipotoxic microenvironment, which leads to further damage of the hepatic tissue, consequently promoting inflammation and fibrogenesis (Buzzetti et al., 2016). More recent investigation has hypothesized that appearance of NASH is the result of the effects of signals deriving from multiple sites, including the gut, the adipose tissue, the muscle, and the liver itself, as illustrated as the “multiple-hits” hypothesis (Tilg and Moschen, 2010). The mechanisms underlying liver fibrosis are intricate and involve the interplay of multiple factors. Among these, a key role is played by the cross-talk between various liver-resident and infiltrating cellular subsets, which produce and secrete different soluble mediators (cytokines and chemokines) (Weiskirchen et al., 2018). In most cases, tissue injury induces an inflammatory response involving the local vascular system, immune cells, and release of endocrine and neurological factors. In this context, non-parenchymal cells [endothelial and hepatic stellate cells (HSCs)] and resident or recruited immune cells [macrophages, dendritic cells (DCs), and mast cells] secrete a variety of pro-inflammatory molecules such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), pro-fibrotic factors including transforming growth factor-β (TGF-β) and pro-apoptotic mediators, as well as reactive oxygen species (Tilg and Diehl, 2000). All together, these signals lead to the activation of matrix-producing cells (including HSCs) and consequently to myofibroblast trans-differentiation (Weiskirchen et al., 2018).
NAFLD not only is related to obesity, hypertension, and inflammation but also is closely associated with insulin resistance (IR), metabolic syndrome (MetS), and type 2 diabetes (T2D) (Gentilini et al., 2016). A recent meta-analysis of published prospective studies has investigated for the first time the association between the presence of NAFLD and the risk of developing T2D and MetS. In particular, it has been observed that NAFLD (as diagnosed by either serum liver enzymes or ultrasonography) predicts T2D development over a median follow-up of 5 years in a pooled population of patients from 20 prospective studies. Moreover, NAFLD was also associated with an increase in MetS incidence over a median follow-up of 4.5 years in a pooled population of patients from eight prospective studies (Ballestri et al., 2016). Importantly, IR has been shown to be crucial for NAFLD progression. Indeed, approximately 80% of obese and diabetic patients are affected by NAFLD (Marchesini et al., 1999). IR is defined as the decreased ability of tissues to respond to insulin signals, and diverse types may be distinguished, a systemic and a hepatic insulin resistance. Systemic IR is characterized by the inability of insulin to diminish blood glucose levels in an appropriate manner due to the impairment of GLUT4 receptor translocation to the surface membrane of the muscle cell, leading to insulin-dependent lower glucose uptake (Petersen and Shulman, 2017). Hepatic IR is described by cessation of insulin-induced suppression of hepatic glucose production and increased stimulation of lipogenesis (Petersen and Shulman, 2017).
Interestingly, insulin also controls lipid metabolism, as it enhances fatty acid re-esterification into triglyceride in adipocytes and the liver. Metabolic actions of insulin are mediated by the PI3K–AKT/PKB pathway (Cohen, 2006), which is phosphorylated by the insulin receptor through two major substrates, insulin receptor substrate 1 and 2 (IRS-1 and IRS-2). Well-established AKT/PKB substrates include GSK-3, a glycogen synthesis regulator, FOXO transcription factors, which upon phosphorylation inhibit transcription of FOXO-dependent gluconeogenic genes (Carter and Brunet, 2007), and sterol regulatory element-binding protein 1c (SREBP-1c), thus enhancing expression of rate-limiting glycolytic and lipogenic enzymes (Foretz et al., 1999; Foufelle and Ferré, 2002).
Also, promoting de novo lipogenesis in the liver, mediated by SREBP-1c, IR inhibits lipid export in the form of triglyceride-rich very-low-density lipoprotein (VLDL), hepatic FFA oxidation, and triglyceride (TG) accumulation, the major form of lipids stored in NAFLD patients (Browning and Horton, 2004).
Liver is the principal site of lipid metabolism; hepatic necro-inflammation has a crucial atherogenic role because it exacerbates systemic IR and promotes atherogenic dyslipidemia, with increased triglycerides, decreased high-density lipoprotein (HDL)-cholesterol, and increased low-density lipoprotein (LDL)-cholesterol (Nobili et al., 2010). Moreover, increased levels of highly atherogenic small dense type A LDL-cholesterol and of oxidized LDL-cholesterol are frequently detected in NAFLD. The main alteration in atherogenesis is the TG hepatic overproduction of as well as cholesterol-enriched VLDL particles.
NAFLD as a Risk Factor for Cardiovascular Diseases
NAFLD has been recognized as strong predictor of increased carotid intima-media thickness, independent of other known cardio-metabolic risk factors.
Hepatic fat accumulation may be an important determinant of the relationship between NAFLD and atherosclerosis. Recently, it has been proposed that fatty liver is not per se a risk factor for atherosclerosis, unless it is associated with metabolic derangements. It has been suggested that there might be two different forms of fatty liver disease: one mainly related to metabolic abnormalities and another due primarily to genetic factors, characterized by higher risk of progressive liver damage (Sookoian and Pirola, 2011; Hamaguchi et al., 2007).
NAFLD is associated with adverse metabolic and atherosclerosis risk profiles (Fox et al., 2007; Neeland et al., 2013). From the metabolic point of view, the biological mechanism responsible for NAFLD-associated atherogenesis could be due to the crosstalk between visceral adipose tissue (VAT), gut, muscle tissue, and liver (Tilg and Moschen, 2010). Indeed, expanded and inflamed VAT releases molecules, such as adipokines, IL-6, and TNF-α, potentially involved in IR and cardiovascular disease (CVD) development (Fargion et al., 2014). Moreover, dietary chylomicrons and de novo lipogenesis contribute to the increased hepatic FFA pool as well as the development of NAFLD (Kleiner and Brunt, 2012).
Lipid accumulation in the liver leads to sub-acute inflammation followed by cytokine production via the NF-kB pathway. In particular, the activation of NF-kB leads to increased transcription of several pro-inflammatory genes that mediate the progression of systemic and low-grade inflammation. The increase in adipose tissue and chronic inflammation also cause an imbalance in adipokine secretion, in particular a reduction of adiponectin. Adiponectin has been shown to have anti-inflammatory and anti-fibrotic capacity (Di Maira et al., 2018; Marra et al., 2008), and its low levels are associated with high fat content (Bugianesi et al., 2005) and the progression from steatosis and CVD to NASH and CV-atherosclerosis, respectively (Matsuzawa et al., 2004). NASH is involved in atherogenesis through the systemic release of pro-atherogenic mediators (C-reactive protein, IL-6, and TNF-α) and hypercoagulation and hypo-fibrinolysis induction mediated by fibrinogen, factor VII, and plasminogen-activator inhibitor-1 (Kotronen and Yki-Järvinen, 2008; Targher et al., 2008). In this way, the liver becomes a source of pro-atherogenic molecules that amplifies arterial injury. In line with these results, growing evidence indicates that atherosclerosis is proportional to the severity of liver damage (Alkhouri et al., 2010) (Figure 1).
Figure 1 Schematic representation of key mechanisms responsible for NAFLD associated-atherosclerosis. NAFLD contributes to a more atherothrombotic risk profile via atherogenic dyslipidemia, hepatic/systematic insulin resistance and increased secretion of several proinflammatory and pro-coagulant mediators. NAFLD, nonalcoholic fatty liver disease; HSCs, hepatic stellate cells; FFA, free fatty acids; LDL, low-density lipoproteins; KCs, kupffer cells.
The importance of NAFLD and its close association with CVD development has been highlighted by two meta-analyses. Notably, in a systematic meta-analysis of 34 cross-sectional and prospective cohort studies, an increase in coronary artery disease, hypertension, and atherosclerosis in NAFLD patients was observed, although no association between NAFLD/NASH and with overall or CVD-related mortality was shown (Wu et al., 2016). Additionally, (Targher et al., 2016) have described a strong correlation between NAFLD and increased risk of fatal and non-fatal CVD events, increased carotid intima-media thickness, increased coronary artery calcification, impaired flow-mediated vasodilation, and arterial stiffness. Indeed, several mechanisms correlated with NAFLD pathogenesis are involved in atherosclerosis and include genetic predisposition, reduced levels of adiponectin, IR, atherogenic dyslipidemia, oxidative stress, chronic inflammation, and altered production of pro- and anti-coagulant factors (Francque et al., 2016). Recently, a systematic review (Zhou et al., 2018) has described a two-fold increase in risk of CVD in diabetic NAFLD patients compared with non-NAFLD group, confirming other previous findings (Targher et al., 2007; Hamaguchi et al., 2007). Likewise, other two independent studies found that TG to high-density lipoprotein cholesterol ratio (TG/HDL-C) could be considered a better NAFLD predictor compared to other several lipid parameters and markers of liver injury (Ren et al., 2019; Fan et al., 2019).
Remarkably, also several polymorphisms associated with predisposition of NAFLD progression have been identified. Among the most validated factors, the Patatin-like phospholipase-3 (PNPLA3)/adiponutrin, rs738409 C > G SNP, I148M (Valenti et al., 2010) variant is involved both in hepatic lipid remodeling and in lipoprotein secretion, determining a greater predisposition to NASH (He et al., 2010; Ruhanen et al., 2014). Indeed, there is dissociation between de novo lipogenesis and the severity of hepatic steatosis in carriers of the I148M variant (Mancina et al., 2015). The involvement of the PNPLA3 variant has been observed also in lean subjects, where the presence of PNPLA3 GG genotype is correlated with a more severe liver and cardiovascular damage (Fracanzani et al., 2017). Among NAFLD patients, with minor metabolic alterations, the presence of GG PNPLA3 makes the subjects more susceptible to liver and CVDs, amplifying the effects of environmental factors (Fracanzani et al., 2017). In addition, carotid plaques have been independently associated not only with well-known risk factors for atherosclerosis but also with the PNPLA3 GG genotype (Petta et al., 2013).
Moreover, the transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 C > T SNP, which encodes the loss of function E167K variant, has been associated with higher risk of NAFLD progression but with lower risk of cardiovascular events (Pirazzi et al., 2012). This protective effect of the E167K variant reflects the reduced circulating levels of atherogenic lipoproteins, because of higher intracellular lipid retention, mainly TGs and cholesterol, in hepatocytes. The mechanism seems related to the reduction of VLDL secretion, thus resulting in TG accumulation and consequent steatosis (Dongiovanni et al., 2015).
Activation of Macrophages Depends on Their Metabolic State
In the liver, resident macrophages, the Kupffer cells are central players in the development of NASH by recruiting inflammatory immune cells and secreting pro-inflammatory cytokines (Sica et al., 2014; Raggi et al., 2015; Raggi et al., 2017). Importantly, the balance between M1 and M2 macrophages (Box 1) mediates the progression or resolution of liver fibrosis. Intriguingly, M1-M2 functional changes have been shown to be dependent on underlying metabolic changes (O’Neill and Pearce, 2016).
Box 1. Macrophage polarization.
In response to various signals, activated macrophages differentiate into two main subsets: M1 (classically activated) and M2 (alternatively activated). M1 macrophages are stimulated by LPS, INF-γ, TNF-α, and/or granulocyte macrophage colony-stimulating factor (GM-CSF) to produce inflammatory mediators, including TNF-α, IL-1β, IL-6, IL-8, IL-12, chemokine (C-C motif) ligand 2 (CCL2/MCP-1), reactive oxygen species (ROS), and reactive nitrogen intermediates (RNI), promoting inflammatory responses and HSC activation (Nathan, 2002). M2 macrophages regulate inflammatory reactions and tissue repair and can be distinguished in diverse subtypes, each one induced by different cytokines and eliciting different signals. In particular, M2a macrophages (CD206/mannose receptor+ CD209/DC-SIGN+ CD163− CD16− MerTK−) are stimulated by IL-4 and/or IL-13 and induce mainly a Th2 response. M2b macrophages are stimulated by immune complexes or LTR ligands and are involved in Th2 activation and immune regulation, producing IL-10 and inflammatory cytokines. Finally, M2c macrophages (CD206high CD209− CD163+ CD16+ MerTK+) are stimulated by macrophage colony-stimulating factor (M-CSF) plus IL-10 and TGF-β or by glucocorticoids, are characterized by their ability to secrete IL-10, which, in turn, is amplified by Gas-6 secretion in an autocrine manner, via MerTK signaling, and are involved in immune suppression, tissue repair, matrix remodeling, and clearance of apoptotic cells (Zizzo et al., 2012; Martinez et al., 2006).
In the lean adipose tissue, M2 macrophages produce high amounts of ATP (∼30 per glucose) through oxidative phosphorylation, a biochemical process slower than glycolysis (O’Neill et al., 2016). In contrast, increased lipid storage in obesity is associated with adipocyte dysfunction and a pro-inflammatory response, with an increase in M1-polarized pro-inflammatory macrophages (Norata et al., 2015). In particular, activation of immune receptors, such as TLRs, IL-1 receptor type I, and TNF-R, results in activation of NF-kB and JNK signaling, which can induce serine phosphorylation of IRS-1 and IRS-2 and thereby inhibition of downstream insulin signaling (McNelis and Olefsky, 2014; Marra, 2008).
In M1 macrophages, upregulation of glycolytic metabolism feeds the pentose phosphate pathway (Van den Bossche et al., 2017). Although glycolysis produces only a small amount of energy (two molecules of ATP per glucose) (Nagy and Haschemi, 2015), this pathway supports inflammatory macrophage responses by generating NADPH, utilized by inducible NO synthase (iNOS) to produce NO or by NADPH oxidase to produce ROS, both necessary to sustain the antimicrobial activity of pro-inflammatory macrophages (Modolell et al., 1995). Moreover, glycolysis generates pyruvate to fuel the tricarboxylic acid cycle. In M1 macrophages, this cycle is interrupted after citrate and succinate (Jha et al., 2015; O’Neill, 2015). Increased synthesis of acetyl coenzyme A from citrate determines the synthesis of free fatty acids (FFAs), lipids, and prostaglandins (Infantino et al., 2011; Infantino et al., 2013). Up-regulation of proteins involved in the uptake [e.g., CD36 (Bassaganya-Riera et al., 2009)], esterification [e.g., diacylglycerol O-acyltransferase (Koliwad et al., 2010)], and oxidation [e.g., long-chain 3-hydroxyacyl-CoA dehydrogenase (Vats et al., 2006)] of FFAs could provide energy for M2 cells to restore tissue homeostasis (Shapiro et al., 2011). These processes would allow a reduction of FFA concentration by reducing IR and inflammation (Vats et al., 2006) (Figure 2).
Figure 2 Macrophage-mediated functions to metabolic activities. In diagram on the left are depicted tissue features in the lean state associate with M2- macrophage polarization, while in diagram on the right are depicted tissue features during inflammation and insulin resistance associate with M1-macrophage polarization.
MerTK in the Activation of Anti-Inflammatory M2c Macrophages
MerTK represents the second member of Tyro-3, Axl, and Mer (TAM) receptor tyrosine kinase (RTK) family to be described (Linger et al., 2008).These receptors are characterized by adhesion molecule-like domains in the extracellular region, mimicking the structure of neural cell adhesion molecule important in cell–cell contacts, which contains five Ig domains and two fibronectin type III domains (Yamagata et al., 2003). The best-studied ligands for MerTK are the Vit-K modified-carboxylated proteins growth arrest-specific 6 (Gas-6) and Protein-S (Mark et al., 1996; Anderson et al., 2003). These glycoproteins share ∼44% of homology and have analogous domain structure, consisting of an N-terminal-carboxyl-glutamic acid (Gla) domain, four tandem epidermal growth factor (EGF)-like repeats, and a C-terminal sex hormone-binding globulin-like region (SHBG) containing 2 laminin G (LG) repeats (Mark et al., 1996). Gas-6 and Protein-S are biologically active following the carboxylation of the Gla-domain through a vitamin K-dependent reaction (Stenhoff et al., 2004). This domain mediates the Ca2+-dependent binding to negatively charged membrane phospholipids, such as phosphatidylserine exposed on the surface of apoptotic cells (Huang et al., 2003). LG domains are involved in the ligand–receptor interaction by forming a V-shaped structure, stabilized by a calcium-binding site (Sasaki et al., 2002). In human plasma, protein-S is highly concentrated (0.30 µM/L) (Rezende et al., 2004) (approximately 1,000 times higher), compared to Gas-6 (0.16–0.28 nM/L) (Balogh et al., 2005), conceivably due to the involvement of protein-S in the coagulation pathways, where it functions as a co-factor for protein C during factor Va and VIIIa inactivation (Heeb, 2008). Gas-6 is expressed mainly in vascular smooth muscle and endothelial cells, and it is frequently upregulated after tissue damage (Ekman et al., 2010).
MerTK is normally expressed in monocytes/macrophages, DCs, NK cells, NKT cells, HSCs, megakaryocytes, platelets, epithelial tissue, and reproductive tissue (Behrens et al., 2003; Petta et al., 2016). M2c macrophages express MerTK at high levels and display a marked capability to clear apoptotic bodies, a physiological process defined as efferocytosis (Zizzo et al., 2012). Interestingly, it has been demonstrated that M2c polarization is closely associated with MerTK upregulation, and detection of M2c receptors predicts MerTK expression (Zizzo et al., 2012). Indeed, MerTK expression and Gas-6 secretion follow the expression of specific M2c macrophages CD163 and CD16. This specific macrophage phenotype can be induced by M-CSF or dexamethasone, and IL-10 could enhance M-CSF effects. In addition, M2c macrophages are able to release Gas-6, which can, in turn, amplify IL-10 secretion in an autocrine manner, via MerTK signaling (Zizzo et al., 2012). Gas-6, linked to the externalized phosphatidylserine, activates MerTK, initiating the phagocytic process and inducing the activation of downstream pathways, such as ERK, P38, MAPK, FAK, AKT, and STAT-6, that mediate transcriptional events, leading to a decrease of pro-inflammatory cytokines, such as IL-12, and increase in inflammatory repressors, including IL-10 and TGF-β, thus generating an anti-inflammatory milieu (Tibrewal et al., 2008).
MerTK signaling plays a central role in the suppression of the innate immune response, as demonstrated in experimental models of endotoxemia, in which MerTK knockout mice exhibit an extreme activation of inflammatory responses and ineffective resolution of inflammation, mediated by elevated levels of TNF-α and IL-1 (Lee et al., 2012). MerTK acts by maintaining both central and peripheral tolerance, through different mechanisms, including efferocytosis. It is already well-described MerTK overexpression in murine models of fibrogenesis and in patients with NASH and severe fibrosis (Petta et al., 2016). Indeed, in genome-wide association studies, it has been reported that the MERTK locus rs4374383 G > A correlates with decreased hepatic MerTK expression, thus protecting against liver fibrosis in chronic hepatitis C and NAFLD (Patin et al., 2012; Petta et al., 2016). The same G > A variant has been found to be associated with cardio-metabolic derangement and nutritionally induced inflammation and could contribute in this way to liver and cardio-metabolic disease (Musso et al., 2017). Moreover, it has been shown that in human NAFLD specimens, MerTK is mainly expressed in macrophages and HSCs loosely aggregated within inflammatory foci (Petta et al., 2016). MerTK signaling has been recently studied also in humans with both acute liver failure syndromes and acute-on-chronic liver failure, where a significant cause of morbidity is sepsis. Triantafyllou et al. (Triantafyllou et al., 2018) have shown an expansion of MerTK-positive cells in circulatory and tissue compartments of patients with acute liver failure compared with healthy and cirrhotic controls, together with a concomitant increase in Gas-6 and in MerTK phosphorylation.
Notably, in response to acute liver injury, MerTK mediates downregulation of inflammatory cascades contributing to hepatic immune regulation by preventing autoreactive T cell development. However, in the context of chronic inflammation, MerTK promotes HSC activation, thus resulting in excessive fibrogenesis by abundant collagen and extracellular matrix proteins secretion (Petta et al., 2016).
Various therapies targeting MerTK are currently under development. Small-molecule tyrosine kinase inhibitors such as UNC569 (Christoph et al., 2013), UNC1062 (Schlegel et al., 2013), and UNC1666 (Lee-Sherick et al., 2015) have been recently described. These compounds competitively bind MerTK in its catalytic site, impeding phosphorylation and activation of the kinase domain. Treatment with these inhibitors causes a decrease in MerTK downstream signaling. Next-generation inhibitors have also been reported, including UNC2025, a potent, orally bioavailable inhibitor (Zhang et al., 2014). Other agents include Mer590, a monoclonal antibody that directly binds to the extracellular domain and induces internalization and degradation of MerTK (Cummings et al., 2014).
Small-molecule inhibitors and monoclonal antibodies are the main drugs that are currently used to inhibit signaling pathways by interfacing with specific molecules. Nevertheless, any targeted therapy has its own limitations. Although identifying a specific molecular target is crucial for NAFLD-associated cardiovascular treatment, targeting only a single molecule may not be completely determinant of these complex diseases. Other limitations include toxicity during the treatment, as well as mechanisms of resistance to molecular-targeted drugs.
Macrophage Nuclear Receptors Control MerTK Expression in Lipid Metabolism NAFLD Associated
Macrophage polarization is an important mechanism for the regulation of inflammatory response, and it is finely controlled by the nuclear receptor superfamily members peroxisome proliferator activated receptors (PPARs) (α, β/δ, and γ isotypes) and liver X receptors (LXRs) (LXR-α and LXR-β) (Rigamonti et al., 2008). These transcription factors form heterodimers with retinoid X receptors (RXR) (α and β isotypes) and, upon binding a lipid or synthetic ligand, mediate gene expression through trans-activation (Szanto and Roszer 2008). Nuclear receptors have considerable roles in the modulation of macrophage functions. Their ligands influence the transcription of genes regulating lipid homeostasis, pro-inflammatory cytokine production, resolution of inflammation, and synthesis of mediators that promote tissue healing (Rőszer et al., 2013; Menendez-Gutierrez et al., 2012). PPAR-γ can be activated by metabolic signals (i.e., polyunsaturated fatty acids and lipoproteins) (Nagy et al., 1998), by inflammatory mediators (i.e., eicosanoids) (Kliewer et al., 1997), or by immunologic signals (i.e., cytokines) (Huang et al., 1999). PPAR-γ activation results in lipid uptake through the scavenger receptor CD36, and β-oxidation of fatty acids (Szanto and Roszer, 2008) is associated to macrophage polarization into M2a cells (Bouhlel et al., 2007). LXRs are oxysterol-activated transcription factors that sense elevated cellular cholesterol (Repa and Mangelsdorf, 2002). PPAR-γ and LXR activities are coordinated, PPAR-γ is in fact able to activate LXRs, but in certain conditions, PPAR-γ and LXRs exert opposing roles (Szanto and Roszer, 2008). In M2a macrophages, IL-4 stimulates the increase of PPAR-γ expression and LXR-α downregulation (Chinetti-Gbaguidi et al., 2011). LXRs are important for both apoptotic cell clearance and suppression of the inflammatory response during their phagocytosis. PPARs and LXRs control the transcription of many receptors, including MerTK.
Accumulation of excess lipoprotein-derived cholesterol in macrophages activates LXRs that, in turn, trigger the induction of ABC transporter, mediating cholesterol efflux (Castrillo and Tontonoz, 2004) and the upregulation of MerTK in mice (A-Gonzalez et al., 2009) and in humans (Zizzo and Cohen, 2015). Gonzalez et al. have demonstrated that phagocytosis of apoptotic cells activates LXRs, probably through the accumulation of membrane-derived cholesterol. LXRs, in turn, activate transcription of MerTK, generating a positive feedback to promote further efferocytosis, a process that mediates the increased expression of ABC transporter genes such as ABCA-1 and ABCG-1, involved in the efflux of the excess cholesterol and immunosuppression (A-Gonzalez et al., 2009). These results indicate that the LXR-dependent regulation of MerTK is important for normal immune homeostasis. MERTK-/- and LXRs DKO mice share a series of features, including amplified pro-inflammatory responses and increased susceptibility to both autoimmunity and atherosclerosis (Ait-Oufella et al., 2008; Cohen et al., 2002).
Role of MerTK in Atherosclerosis Process
Atherosclerotic lesions are clinically silent, and the acute cardiovascular events can be consequent to evolution to necrotic plaques (Virmani et al., 2000). At first, apoptotic cells are efficiently cleared by neighboring macrophages to limit overall lesion cellularity (Tabas, 2005). Here, efferocytosis is rapid and without inflammation. In physiological conditions, apoptotic cells are engulfed and degraded in phagolysosomes, and macrophages become overloaded with macromolecular constituents and cholesterol. In advanced atherosclerosis, the persistence of chronic inflammatory stimuli promotes lesion destabilization and susceptibility to heart attack and stroke. The role of inflammation in promoting atherosclerosis is well documented. Indeed, in advanced plaques, apoptotic foam cells, induced by chronic endoplasmic reticulum stress, elicit inflammatory responses (Li et al., 2013). In addition, endoplasmic reticulum stress is strongly correlated with plaque rupture (Li et al., 2006). Two processes contribute to post-apoptotic necrosis and defective efferocytosis and are impaired to resolve the inflammation response (Schrijvers et al., 2005; Libby, 2002; Tabas, 2010). Defective efferocytosis may be manifest at multiple levels, including improper presentation of apoptotic bodies ligands, failure to secrete come find me recruitment signals, or defects at the level of phagocytes (Vandivier et al., 2006). Efferocytosis is impaired in this last stage, and defective MerTK contributes, at least in part, to expansion of necrotic plaque (Tabas, 2005). In this regard, evidence demonstrates that mice lacking MerTK have shown a defect in efferocytosis, and this correlated with increased inflammation and necrosis within the plaque (Ait-Oufella et al., 2008; Thorp et al., 2008). Moreover, macrophages near the necrotic core of human atheroma showed lower MerTK expression than those in the peripheral lesions (Garbin et al., 2013). Finally, in the advanced atherosclerosis, accumulation of lipids and ROS increases levels of oxidized phospholipids. These lipids can bind to scavenger receptors and may compete for apoptotic cell recognition, compromising efferocytosis mechanisms (Gillotte-Taylor et al., 2001). A recent study shows that in the lesions, prevention of dead cells’ uptake is mediated by some apoptotic cells displaying a don’t-eat-me molecule called CD47, which is usually lost during apoptosis (Kojima et al., 2016).
Efferocytosis can be impaired by inactivation of MerTK under some inflammatory conditions (Sather et al., 2007). In particular, oxidized LDLs induce the expression of toll-like receptor 4 (TLR4), increase secretion of pro-atherogenic cytokines, such as TNF-α and IL-1β, and reduce secretion of anti-inflammatory cytokines, such as TGF-β and IL-10 (Bae et al., 2009). This pro-inflammatory environment impairs efferocytosis, promoting increased lipid uptake, which amplified phagocytosis, and reducing MerTK expression levels on the macrophage surface (Miller et al., 2003). The decrease of MerTK expression is associated with its cleavage by the metalloproteinase ADAM17. In human atheromas, macrophages adjacent to the necrotic core have higher ADAM17 than those in peripheral lesion (Garbin et al., 2013). Multiple athero-inflammatory stimuli, such as oxidative stress, hypoxia, and oxidized ligands, are able to promote ADAM17 activity (Sather et al., 2007; Garbin et al., 2013). Efferocytosis is suppressed by destroying the receptor and creating soluble Mer (sol-Mer), which competes for the binding molecules Gas-6 and Protein-S. Interestingly, oxidized LDLs, promoting MerTK cleavage and defective efferocytosis, can activate necroptotic pathways within advanced plaques, favoring the development of necrotic core (Karunakaran et al., 2016). In a recent study, it has been demonstrated that oxidized LDLs are able to increase sol-Mer levels and decrease MerTK expression in the surface of wild-type macrophages but not in macrophages pre-treated with ADAM17 inhibitor or in macrophages that express cleavage-resistant MerTK (Cai et al., 2016). Of note, MerTK-mediated efferocytosis might be limited by availability of Gas-6. In this regard, vascular smooth muscle cells appear to be a major source of Gas-6 within the lesions (Melaragno et al., 1999; Yin et al., 2000). It has been reported that vulnerable plaques have a paucity of smooth muscle cells in areas next to rupture (Clarke et al., 2006).
Nuclear Receptors as Macrophage Therapeutic Target
Nuclear receptors such as PPARs and LXRs are important transcription factors associated with the specific accessory functions of macrophages. PPAR-γ exhibits great potentiality as a drug target in the therapy of inflammation-related diseases. Thiazolidinediones are insulin sensitizers used to improve glycemic control in T2DM patients. However, they may cause weight gain, fluid retention that can precipitate cardiac failure and bone fractures, and risk of bladder cancer (Cariou et al., 2012). In order to eliminate the onset of these effects, further research into new PPAR-γ modulators is required.
GW9662 is a potent, irreversible, and selective PPAR-γ antagonist. Zizzo et al. have shown that this PPAR-γ antagonist induces macrophage differentiation towards M2c-like (CD206+ CD163+ CD16+) cells and upregulation of the MerTK/Gas-6 axis. It has shown that among the novel small molecules derived from GW9662, BZ-26 has a stronger interaction with PPAR-γ and higher transcriptional inhibitory activity of PPAR-γ compared with GW9662. BZ-26 inhibits inflammatory macrophage differentiation of THP1 human monocytic cell line (Bei et al., 2016). Moreover, BZ-26 attenuates the inflammatory responses in LPS-triggered acute inflammation mouse model down-regulating peripheral TNF-α and IL-6 level. BZ-26 inhibits NF-kB transcriptional activity and abolishes LPS-induced nuclear translocation of P65. These data demonstrate that PPAR-γ, besides being a ligand-activated nuclear receptor implicated in regulation of lipid and glucose metabolism, is a fundamental transcription factor for differentiation and activation of macrophages. PPAR-γ could represent an important therapeutic target to modulate inflammation via inhibiting inflammatory macrophages.
LXRs are important regulators of cholesterol, free fatty acids, and glucose metabolism. LXRs drive cholesterol efflux in macrophages (through ABCA-1 and ABCG-1) and support reverse cholesterol transport by cholesterol conversion to bile acids and excretion in the liver. Moreover, their activation is important in regulating immune processes and in inhibiting inflammatory gene expression (Joseph et al., 2003). It has been shown that T0901317, a synthetic LXR agonist, upregulates MerTK expression during the polarization of monocytes to macrophages independently of M2c polarization, with significant effects already occurring at low doses (Zizzo and Cohen, 2015), confirming previously obtained data in mice (A-Gonzalez et al., 2009). Unfortunately, synthetic LXR agonists, such as T0901317, mediate reverse cholesterol transport not only in the macrophage but also in other cell types, including hepatocytes (Grefhorst et al., 2002). Activation of cholesterol efflux from both sources induces the activation of a lipogenic program, mediated by SREBP (Grefhorst et al., 2002), which induces remarkable steatosis and dyslipidemia in the liver in mouse models and human patients (Kirchgessner et al., 2016). These conditions make LXR’s therapeutic targeting unsustainable. Recently, Muse et al. have identified two synthetic compounds: N,N-dimethyl-3β-hydroxycholenamide (DMHCA) and methylpiperidinyl-3β-hydroxycholenamide (MePipHCA), which act as potent activators of LXR target genes involved in cholesterol efflux (e.g., ABCA-1 and ABCG-1) in human and murine macrophages, while having no effect on the expression of lipogenic SREBP targets (e.g., Fasn) in the liver (Magida and Evans, 2018). Interestingly, DMHCA and MePipHCA activity on Kupffer cells does not induce target gene activation in the liver (Muse et al., 2018). These two LXR agonists exhibit anti-atherosclerotic activity without causing substantial hypertriglyceridemia in mice; therefore, they might represent a new class of athero-protective agents (Muse et al., 2018). It has been demonstrated the efficacy of DMHCA and MePipHCA in suppressing inflammation without causing liver lipid accumulation or liver injury in mouse models (Yu et al., 2016) (Table 1). Further studies will be needed to evaluate the effect of these compounds on macrophage polarization and activation. A limitation of these compounds is the large dose for in vivo efficacy. Therefore, the pharmacokinetic profile of these molecules will need to be improved.
Table 1 Overview of nuclear receptors functions modulating lipid metabolism in macrophages and actions mediated by their synthetic ligands.
Conclusions and Future Perspectives
Although there is a clear association between NAFLD and the progression of atherosclerotic lesions, the underlying mechanisms are only partially delineated. Lipid metabolism plays key roles in the polarization of macrophages, which, in turn, influences the pathogenesis of lipid-related diseases (Figure 1). The huge complexity of NAFLD and CVD pathogenesis suggests a multitarget pharmacological approach, in which macrophages represent an intriguing target.
In this scenario, the nuclear receptor-dependent regulation of MerTK is important for immune homeostasis and MerTK regulates the pro-inflammatory responses reducing both autoimmunity and atherosclerosis.
Author Contributions
MP, SG, RMP, GL, CR, SP, and FM contributed to analysis of publications, drafting of the manuscript, and critical revision of the content.
Funding
Funding for this work was partially provided by Italian Foundation of Cancer Research award (MFGA17588) to CR and (IG17786) to FM as well as by Istituto Toscano Tumori (DDRT 6685) to FM.
Conflicts of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), MerTK (myeloid-epithelial-reproductive tyrosine kinase), hepatocellular carcinoma (HCC), cardiovascular diseases (CVD), insulin resistance (IR), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), transforming growth factor-β (TGF-β), apoptotic cells (ACs), free fatty acids (FFAs), de novo lipogenesis (DNL), sterol regulatory element-binding protein 1c (SREBP-1c), patatin-like phospholipase-3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), low-density lipoproteins (VLDL), triglycerides (TGs), high-density lipoproteins (HDL), low-density lipoproteins (LDL), growth arrest-specific 6 (Gas-6), carboxyl-glutamic acid (Gla), epidermal growth factor (EGF), sex hormone-binding globulin-like (SHBG), laminin G (LG), visceral adipose tissue (VAT), granulocyte macrophage colony-stimulating factor (GM-CSF), reactive oxygen species (ROS), reactive nitrogen intermediates (RNI), hepatic stellate cells (HSCs), macrophage colony-stimulating factor (M-CSF), growth arrest-specific-6 (Gas-6), matrix metalloproteinases (MMPs), inducible NO synthase (iNOS), hypoxia-inducible factor (HIF), pyruvate kinase M2 (PKM2), peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), retinoid X receptors (RXRs), dendritic cells (DCs), ATP-binding cassette transporter A1 and G1 (ABCA-1 and ABCG-1), reverse cholesterol transport (RCT), apolipoprotein B (APO-B), smooth muscle cells (VSMCs), phosphatidylserine (PtSer), toll-like receptor 4 (TLR4), soluble fragment of MerTK (sol-Mer), specialized pro-resolving mediators (SPMs), suppression of cytokine signaling-1 and 3 (SOCS-1 and SOCS-3), N,N-dimethyl-3β-hydroxycholenamide (DMHCA), methylpiperidinyl-3β-hydroxycholenamide (MePipHCA).
References
A-Gonzalez, N., Bensinger, S. J., Hong, C., Beceiro, S., Bradley, M. N., Zelcer, N., et al. (2009). Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31 (2), 245–258. doi: 10.1016/j.immuni.2009.06.018
Ait-Oufella, H., Pouresmail, V., Simon, T., Blanc-Brude, O., Kinugawa, K., Merval, R., et al. (2008). Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28 (8), 1429–1431. doi: 10.1161/ATVBAHA.108.169078
Alkhouri, N., Tamimi, T. A., Yerian, L., Lopez, R., Zein, N. N., Feldstein, A. E. (2010). The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig. Dis. Sci. 55 (9), 2644–2650. doi: 10.1007/s10620-009-1075-y
Anderson, H. A., Maylock, C. A., Williams, J. A., Paweletz, C. P., Shu, H., Shacter, E. (2003). Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat. Immunol. 4 (1), 87–91. doi: 10.1038/ni871
Bae, Y. S., Lee, J. H., Choi, S. H., Kim, S., Almazan, F., Witztum, J. L., et al. (2009). Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ. Res. 104 (2), 210–218, 21p following 218. doi: 10.1161/CIRCRESAHA.108.181040
Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., et al. (2016). Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. J. Gastroenterol. Hepatol. 31 (5), 936–944. doi: 10.1111/jgh.13264
Balogh, I., Hafizi, S., Stenhoff, J., Hansson, K., Dahlbäck, B. (2005). Analysis of Gas6 in human platelets and plasma. Arterioscler. Thromb. Vasc. Biol. 25 (6), 1280–1286. doi: 10.1161/01.ATV.0000163845.07146.48
Bassaganya-Riera, J., Misyak, S., Guri, A. J., Hontecillas, R. (2009). PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation. Cell Immunol. 258 (2), 138–146. doi: 10.1016/j.cellimm.2009.04.003
Behrens, E. M., Gadue, P., Gong, S. Y., Garrett, S., Stein, P. L., Cohen, P. L. (2003). The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity. Eur. J. Immunol. 33 (8), 2160–2167. doi: 10.1002/eji.200324076
Bei, Y., Chen, J., Zhou, F., Huang, Y., Jiang, N., Tan, R., et al. (2016). BZ-26, a novel GW9662 derivate, attenuated inflammation by inhibiting the differentiation and activation of inflammatory macrophages. Biomed. Pharmacother. 84, 730–739. doi: 10.1016/j.biopha.2016.08.069
Bouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., et al. (2007). PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6 (2), 137–143. doi: 10.1016/j.cmet.2007.06.010
Browning, J. D., Horton, J. D. (2004). Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2), 147–152. doi: 10.1172/JCI22422
Bugianesi, E., Pagotto, U., Manini, R., Vanni, E., Gastaldelli, A., de Iasio, R., et al. (2005). Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 90 (6), 3498–3504. doi: 10.1210/jc.2004-2240
Buzzetti, E., Pinzani, M., Tsochatzis, E. A. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65 (8), 1038–1048. doi: 10.1016/j.metabol.2015.12.012
Cai, B., Thorp, E. B., Doran, A. C., Subramanian, M., Sansbury, B. E., Lin, C. S., et al. (2016). MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc. Nat. Acad. Sci. U. S. A. 113 (23), 6526–6531. doi: 10.1073/pnas.1524292113
Cariou, B., Charbonnel, B., Staels, B. (2012). Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol. Metab. 23 (5), 205–215. doi: 10.1016/j.tem.2012.03.001
Carter, M. E., Brunet, A. (2007). FOXO transcription factors. Curr. Biol. 17 (4), R113–R114. doi: 10.1016/j.cub.2007.01.008
Castrillo, A., Tontonoz, P. (2004). Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Ann. Rev. Cell Dev. Biol. 20, 455–480. doi: 10.1146/annurev.cellbio.20.012103.134432
Chinetti-Gbaguidi, G., Baron, M., Bouhlel, M. A., Vanhoutte, J., Copin, C., Sebti, Y., et al. (2011). Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ. Res. 108 (8), 985–995. doi: 10.1161/CIRCRESAHA.110.233775
Christoph, S., Deryckere, D., Schlegel, J., Frazer, J. K., Batchelor, L. A., Trakhimets, A. Y., et al. (2013). UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol. Cancer Ther. 12 (11), 2367–2377. doi: 10.1158/1535-7163.MCT-13-0040
Clarke, M. C., Figg, N., Maguire, J. J., Davenport, A. P., Goddard, M., Littlewood, T. D., et al. (2006). Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat. Med. 12 (9), 1075–1080. doi: 10.1038/nm1459
Cohen, P. (2006). The twentieth century struggle to decipher insulin signalling. Nat. Rev. Mol. Cell Biol. 7 (11), 867–873. doi: 10.1038/nrm2043
Cohen, P. L., Caricchio, R., Abraham, V., Camenisch, T. D., Jennette, J. C., Roubey, R. A., et al. (2002). Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196 (1), 135–140. doi: 10.1084/jem.20012094
Cummings, C. T., Linger, R. M., Cohen, R. A., Sather, S., Kirkpatrick, G. D., Davies, K. D., et al. (2014). Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget 5 (21), 10434–10445. doi: 10.18632/oncotarget.2142
Day, C. P., James, O. F. (1998). Steatohepatitis: a tale of two “hits”? Gastroenterology 114 (4), 842–845. doi: 10.1016/S0016-5085(98)70599-2
Del Campo, J. A., Gallego-Durán, R., Gallego, P., Grande, L. (2018). Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). Int. J. Mol. Sci. 19 (3), 1–11. doi: 10.3390/ijms19030911
Di Maira, G., Pastore, M., Marra, F. (2018). Liver fibrosis in the context of nonalcoholic steatohepatitis: the role of adipokines. Minerva Gastroenterol. Dietol. 64 (1), 39–50. doi: 10.23736/S1121-421X.17.02427-8
Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., et al. (2015). Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61 (2), 506–514. doi: 10.1002/hep.27490
Ekman, C., Linder, A., Akesson, P., Dahlbäck, B. (2010). Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit. Care 14 (4), R158. doi: 10.1186/cc9233
Fan, N., Peng, L., Xia, Z., Zhang, L., Song, Z., Wang, Y., et al. (2019). Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 18 (1), 39. doi: 10.1186/s12944-019-0986-7
Fargion, S., Porzio, M., Fracanzani, A. L. (2014). Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J. Gastroenterol. 20 (37), 13306–13324. doi: 10.3748/wjg.v20.i37.13306
Foretz, M., Guichard, C., Ferré, P., Foufelle, F. (1999). Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Nat. Acad. Sci. U. S. A. 96 (22), 12737–12742. doi: 10.1073/pnas.96.22.12737
Foufelle, F., Ferré, P. (2002). New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem. J. 366 (Pt 2), 377–391. doi: 10.1042/BJ20020430
Fox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C. Y., et al. (2007). Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116 (1), 39–48. doi: 10.1161/CIRCULATIONAHA.106.675355
Fracanzani, A. L., Petta, S., Lombardi, R., Pisano, G., Russello, M., Consonni, D., et al. (2017). Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin. Gastroenterol. Hepatol. 15 (10), 1604–1611.e1. doi: 10.1016/j.cgh.2017.04.045
Francque, S. M., van der Graaff, D., Kwanten, W. J. (2016). Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J. Hepatol. 65 (2), 425–443. doi: 10.1016/j.jhep.2016.04.005
Garbin, U., Baggio, E., Stranieri, C., Pasini, A., Manfro, S., Mozzini, C., et al. (2013). Expansion of necrotic core and shedding of Mertk receptor in human carotid plaques: a role for oxidized polyunsaturated fatty acids? Cardiovasc. Res. 97 (1), 125–133. doi: 10.1093/cvr/cvs301
Gentilini, A., Caligiuri, A., Provenzano, A., Marra, F. (2016). Novel aspects in the pathogenesis of nonalcoholic steatohepatitis. Curr. Mol. Med. 16 (8), 710–720. doi: 10.2174/1566524016666161021163252
Gillotte-Taylor, K., Boullier, A., Witztum, J. L., Steinberg, D., Quehenberger, O. (2001). Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J. Lipid. Res. 42 (9), 1474–1482.
Grefhorst, A., Elzinga, B. M., Voshol, P. J., Plösch, T., Kok, T., Bloks, V. W., et al. (2002). Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277 (37), 34182–34190. doi: 10.1074/jbc.M204887200
Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., et al. (2007). Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 13 (10), 1579–1584. doi: 10.3748/wjg.v13.i10.1579
He, S., McPhaul, C., Li, J. Z., Garuti, R., Kinch, L., Grishin, N. V., et al. (2010). A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285 (9), 6706–6715. doi: 10.1074/jbc.M109.064501
Heeb, M. J. (2008). Role of the PROS1 gene in thrombosis: lessons and controversies. Expert Rev. Hematol. 1 (1), 9–12. doi: 10.1586/17474086.1.1.9
Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., et al. (1999). Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400 (6742), 378–382. doi: 10.1038/22572
Huang, M., Rigby, A. C., Morelli, X., Grant, M. A., Huang, G., Furie, B., et al. (2003). Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat. Struct. Biol. 10 (9), 751–756. doi: 10.1038/nsb971
Infantino, V., Convertini, P., Cucci, L., Panaro, M. A., Di Noia, M. A., Calvello, R., et al. (2011). The mitochondrial citrate carrier: a new player in inflammation. Biochem. J. 438 (3), 433–436. doi: 10.1042/BJ20111275
Infantino, V., Iacobazzi, V., Palmieri, F., Menga, A. (2013). ATP-citrate lyase is essential for macrophage inflammatory response. Biochem. Biophys. Res. Commun. 440 (1), 105–111. doi: 10.1016/j.bbrc.2013.09.037
Jha, A. K., Huang, S. C., Sergushichev, A., Lampropoulou, V., Ivanova, Y., Loginicheva, E., et al. (2015). Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42 (3), 419–430. doi: 10.1016/j.immuni.2015.02.005
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., Tontonoz, P. (2003). Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2), 213–219. doi: 10.1038/nm820
Karunakaran, D., Geoffrion, M., Wei, L., Gan, W., Richards, L., Shangari, P., et al. (2016). Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci. Adv. 2 (7), e1600224. doi: 10.1126/sciadv.1600224
Kirchgessner, T. G., Sleph, P., Ostrowski, J., Lupisella, J., Ryan, C. S., Liu, X., et al. (2016). Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils. Cell Metab. 24 (2), 223–233. doi: 10.1016/j.cmet.2016.07.016
Kleiner, D. E., Brunt, E. M. (2012). Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin. Liver Dis. 32 (1), 3–13. doi: 10.1055/s-0032-1306421
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., et al. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Nat. Acad. Sci. U. S. A. 94 (9), 4318–4323. doi: 10.1073/pnas.94.9.4318
Kojima, Y., Volkmer, J. P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., et al. (2016). CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536 (7614), 86–90. doi: 10.1038/nature18935
Koliwad, S. K., Streeper, R. S., Monetti, M., Cornelissen, I., Chan, L., Terayama, K., et al. (2010). DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. J. Clin. Invest. 120 (3), 756–767. doi: 10.1172/JCI36066
Kotronen, A., Yki-Järvinen, H. (2008). Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28 (1), 27–38. doi: 10.1161/ATVBAHA.107.147538
Lee, Y. J., Lee, S. H., Youn, Y. S., Choi, J. Y., Song, K. S., Cho, M. S., et al. (2012). Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice. Toxicol. Appl. Pharmacol. 263 (1), 61–72. doi: 10.1016/j.taap.2012.05.024
Lee-Sherick, A. B., Zhang, W., Menachof, K. K., Hill, A. A., Rinella, S., Kirkpatrick, G., et al. (2015). Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget 6 (9), 6722–6736. doi: 10.18632/oncotarget.3156
Li, B., Zhang, C., Zhan, Y. T. (2018). Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J. Gastroenterol. Hepatol. 2018, 2784537. doi: 10.1155/2018/2784537
Li, Y., Dalli, J., Chiang, N., Baron, R. M., Quintana, C., Serhan, C. N. (2013). Plasticity of leukocytic exudates in resolving acute inflammation is regulated by microRNA and proresolving mediators. Immunity 39 (5), 885–898. doi: 10.1016/j.immuni.2013.10.011
Li, Y., Gerbod-Giannone, M. C., Seitz, H., Cui, D., Thorp, E., Tall, A. R., et al. (2006). Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J. Biol. Chem. 281 (10), 6707–6717. doi: 10.1074/jbc.M510579200
Libby, P. (2002). Inflammation in atherosclerosis. Nature 420 (6917), 868–874. doi: 10.1038/nature01323
Linger, R. M., Keating, A. K., Earp, H. S., Graham, D. K. (2008). TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35–83. doi: 10.1016/S0065-230X(08)00002-X
Ludwig, J., Viggiano, T. R., McGill, D. B., Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55 (7), 434–438.
Magida, J. A., Evans, R. M. (2018). Rational application of macrophage-specific LXR agonists avoids the pitfalls of SREBP-induced lipogenesis. Proc. Nat. Acad. Sci. U. S. A. 115 (20), 5051–5053. doi: 10.1073/pnas.1805128115
Mancina, R. M., Matikainen, N., Maglio, C., Söderlund, S., Lundbom, N., Hakkarainen, A., et al. (2015). Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J. Clin. Endocrinol. Metab. 100 (5), E821–E825. doi: 10.1210/jc.2014-4464
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., et al. (1999). Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107 (5), 450–455. doi: 10.1016/S0002-9343(99)00271-5
Mark, M. R., Chen, J., Hammonds, R. G., Sadick, M., Godowsk, P. J. (1996). Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J. Biol. Chem. 271 (16), 9785–9789. doi: 10.1074/jbc.271.16.9785
Marra, F. (2004). NASH: are genes blowing the hits? J. Hepatol. 40 (5), 853–856. doi: 10.1016/j.jhep.2004.03.005
Marra, F. (2008). Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy. Gut 57 (5), 570–572. doi: 10.1136/gut.2007.141986
Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G., Tiribelli, C. (2008). Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 14 (2), 72–81. doi: 10.1016/j.molmed.2007.12.003
Martinez, F. O., Gordon, S., Locati, M., Mantovani, A. (2006). Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177 (10), 7303–7311. doi: 10.4049/jimmunol.177.10.7303
Matsuzawa, Y., Funahashi, T., Kihara, S., Shimomura, I. (2004). Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24 (1), 29–33. doi: 10.1161/01.ATV.0000099786.99623.EF
McNelis, J. C., Olefsky, J. M. (2014). Macrophages, immunity, and metabolic disease. Immunity 41 (1), 36–48. doi: 10.1016/j.immuni.2014.05.010
Melaragno, M. G., Fridell, Y. W., Berk, B. C. (1999). The Gas6/Axl system: a novel regulator of vascular cell function. Trends Cardiovasc. Med. 9 (8), 250–253. doi: 10.1016/S1050-1738(00)00027-X
Menendez-Gutierrez, M. P., Roszer, T., Ricote, M. (2012). Biology and therapeutic applications of peroxisome proliferator- activated receptors. Curr. Top Med. Chem. 12 (6), 548–584. doi: 10.2174/156802612799436669
Miller, Y. I., Viriyakosol, S., Binder, C. J., Feramisco, J. R., Kirkland, T. N., Witztum, J. L. (2003). Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278 (3), 1561–1568. doi: 10.1074/jbc.M209634200
Modolell, M., Corraliza, I. M., Link, F., Soler, G., Eichmann, K. (1995). Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25 (4), 1101–1104. doi: 10.1002/eji.1830250436
Muse, E. D., Yu, S., Edillor, C. R., Tao, J., Spann, N. J., Troutman, T. D., et al. (2018). Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proc. Nat. Acad. Sci. U. S. A. 115 (20), E4680–E4689. doi: 10.1073/pnas.1714518115
Musso, G., Cassader, M., De Michieli, F., Paschetta, E., Pinach, S., Saba, F., et al. (2017). MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Hum. Mol. Genet. 26 (9), 1785. doi: 10.1093/hmg/ddx126
Nagy, C., Haschemi, A. (2015). Time and demand are two critical dimensions of immunometabolism: the process of macrophage activation and the pentose phosphate pathway. Front. Immunol. 6, 164. doi: 10.3389/fimmu.2015.00164
Nagy, L., Tontonoz, P., Alvarez, J. G., Chen, H., Evans, R. M. (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (2), 229–240. doi: 10.1016/S0092-8674(00)81574-3
Nathan, C. (2002). Points of control in inflammation. Nature 420 (6917), 846–852. doi: 10.1038/nature01320
Neeland, I. J., Ayers, C. R., Rohatgi, A. K., Turer, A. T., Berry, J. D., Das, S. R., et al. (2013). Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 21 (9), E439–E447. doi: 10.1002/oby.20135
Nobili, V., Parola, M., Alisi, A., Marra, F., Piemonte, F., Mombello, C., et al. (2010). Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. Int. J. Mol. Med. 26 (4), 471–476. doi: 10.3892/ijmm_00000487
Norata, G. D., Caligiuri, G., Chavakis, T., Matarese, G., Netea, M. G., Nicoletti, A., et al. (2015). The cellular and molecular basis of translational immunometabolism. Immunity 43 (3), 421–434. doi: 10.1016/j.immuni.2015.08.023
O’Neill, L. A. (2015). A broken krebs cycle in macrophages. Immunity 42 (3), 393–394. doi: 10.1016/j.immuni.2015.02.017
O’Neill, L. A., Kishton, R. J., Rathmell, J. (2016). A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16 (9), 553–565. doi: 10.1038/nri.2016.70
O’Neill, L. A., Pearce, E. J. (2016). Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213 (1), 15–23. doi: 10.1084/jem.20151570
Ofosu, A., Ramai, D., Reddy, M. (2018). Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann. Gastroenterol. 31 (3), 288–295. doi: 10.20524/aog.2018.0240
Parola, M., Pinzani, M. (2018). Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 65, 37–55. doi: 10.1016/j.mam.2018.09.002
Patin, E., Kutalik, Z., Guergnon, J., Bibert, S., Nalpas, B., Jouanguy, E., et al, I.ternational Hepatitis C Genetics Consortium Swiss Hepatitis C Cohort Study Group, French ANRS HC EP 26 Genoscan Study Group. (2012). Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 143 (5), 1244–1252.e12. doi: 10.1053/j.gastro.2012.07.097
Petersen, M. C., Shulman, G. I. (2017). Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol. Sci. 38 (7), 649–665. doi: 10.1016/j.tips.2017.04.004
Petta, S., Valenti, L., Marchesini, G., Di Marco, V., Licata, A., Cammà, C., et al. (2013). PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One 8 (9), e74089. doi: 10.1371/journal.pone.0074089
Petta, S., Valenti, L., Marra, F., Grimaudo, S., Tripodo, C., Bugianesi, E., et al. (2016). MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 64 (3), 682–690. doi: 10.1016/j.jhep.2015.10.016
Pirazzi, C., Adiels, M., Burza, M. A., Mancina, R. M., Levin, M., Ståhlman, M., et al. (2012). Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J. Hepatol. 57 (6), 1276–1282. doi: 10.1016/j.jhep.2012.07.030
Pradere, J. P., Kluwe, J., De Minicis, S., Jiao, J. J., Gwak, G. Y., Dapito, D. H., et al. (2013). Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58 (4), 1461–1473. doi: 10.1002/hep.26429
Raggi, C., Correnti, M., Sica, A., Andersen, J. B., Cardinale, V., Alvaro, D., et al. (2017). Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J. Hepatol. 66 (1), 102–115. doi: 10.1016/j.jhep.2016.08.012
Raggi, C., Invernizzi, P., Andersen, J. B. (2015). Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J. Hepatol. 62 (1), 198–207. doi: 10.1016/j.jhep.2014.09.007
Ren, X. Y., Shi, D., Ding, J., Cheng, Z. Y., Li, H. Y., Li, J. S., et al. (2019). Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. Lipids Health Dis. 18 (1), 47. doi: 10.1186/s12944-019-0984-9
Repa, J. J., Mangelsdorf, D. J. (2002). The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 8 (11), 1243–1248. doi: 10.1038/nm1102-1243
Rezende, S. M., Simmonds, R. E., Lane, D. A. (2004). Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 103 (4), 1192–1201. doi: 10.1182/blood-2003-05-1551
Rigamonti, E., Chinetti-Gbaguidi, G., Staels, B. (2008). Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 28 (6), 1050–1059. doi: 10.1161/ATVBAHA.107.158998
Ruhanen, H., Perttilä, J., Hölttä-Vuori, M., Zhou, Y., Yki-Järvinen, H., Ikonen, E., et al. (2014). PNPLA3 mediates hepatocyte triacylglycerol remodeling. J. Lipid. Res. 55 (4), 739–746. doi: 10.1194/jlr.M046607
Rőszer, T., Menéndez-Gutiérrez, M. P., Cedenilla, M., Ricote, M. (2013). Retinoid X receptors in macrophage biology. Trends Endocrinol. Metab. 24 (9), 460–468. doi: 10.1016/j.tem.2013.04.004
Sasaki, T., Knyazev, P. G., Cheburkin, Y., Göhring, W., Tisi, D., Ullrich, A., et al. (2002). Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. J. Biol. Chem. 277 (46), 44164–44170. doi: 10.1074/jbc.M207340200
Sather, S., Kenyon, K. D., Lefkowitz, J. B., Liang, X., Varnum, B. C., Henson, P. M., et al. (2007). A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109 (3), 1026–1033. doi: 10.1182/blood-2006-05-021634
Schlegel, J., Sambade, M. J., Sather, S., Moschos, S. J., Tan, A. C., Winges, A., et al. (2013). MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J. Clin. Invest. 123 (5), 2257–2267. doi: 10.1172/JCI67816
Schrijvers, D. M., De Meyer, G. R., Kockx, M. M., Herman, A. G., Martinet, W. (2005). Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25 (6), 1256–1261. doi: 10.1161/01.ATV.0000166517.18801.a7
Shapiro, H., Lutaty, A., Ariel, A. (2011). Macrophages, meta-inflammation, and immuno-metabolism. Sci. World J. 11, 2509–2529. doi: 10.1100/2011/397971
Sica, A., Invernizzi, P., Mantovani, A. (2014). Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 59 (5), 2034–2042. doi: 10.1002/hep.26754
Sookoian, S., Pirola, C. J. (2011). Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53 (6), 1883–1894. doi: 10.1002/hep.24283
Stenhoff, J., Dahlbäck, B., Hafizi, S. (2004). Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem. Biophys. Res. Commun. 319 (3), 871–878. doi: 10.1016/j.bbrc.2004.05.070
Szanto, A., Roszer, T. (2008). Nuclear receptors in macrophages: a link between metabolism and inflammation. FEBS Lett. 582 (1), 106–116. doi: 10.1016/j.febslet.2007.11.020
Tabas, I. (2005). Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25 (11), 2255–2264. doi: 10.1161/01.ATV.0000184783.04864.9f
Tabas, I. (2010). Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10 (1), 36–46. doi: 10.1038/nri2675
Tacke, F. (2017). Targeting hepatic macrophages to treat liver diseases. J. Hepatol. 66 (6), 1300–1312. doi: 10.1016/j.jhep.2017.02.026
Tacke, F., Trautwein, C. (2015). Mechanisms of liver fibrosis resolution. J. Hepatol. 63 (4), 1038–1039. doi: 10.1016/j.jhep.2015.03.039
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., et al. (2007). Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (5), 1212–1218. doi: 10.2337/dc06-2247
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., Barbui, C. (2016). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 65 (3), 589–600. doi: 10.1016/j.jhep.2016.05.013
Targher, G., Marra, F., Marchesini, G. (2008). Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51 (11), 1947–1953. doi: 10.1007/s00125-008-1135-4
Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G., Tabas, I. (2008). Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler. Thromb. Vasc. Biol. 28 (8), 1421–1428. doi: 10.1161/ATVBAHA.108.167197
Tibrewal, N., Wu, Y., D'mello, V., Akakura, R., George, T. C., Varnum, B., Birge, R. B. (2008). Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-kappaB transcriptional activation. J Biol Chem 283 (6), 3618–3627. doi: 10.1074/jbc.M706906200
Tilg, H., Diehl, A. M. (2000). Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343 (20), 1467–1476. doi: 10.1056/NEJM200011163432007
Tilg, H., Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (5), 1836–1846. doi: 10.1002/hep.24001
Triantafyllou, E., Pop, O. T., Possamai, L. A., Wilhelm, A., Liaskou, E., Singanayagam, A., et al. (2018). MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. Gut 67 (2), 333–347. doi: 10.1136/gutjnl-2016-313615
Valenti, L., Al-Serri, A., Daly, A. K., Galmozzi, E., Rametta, R., Dongiovanni, P., et al. (2010). Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51 (4), 1209–1217. doi: 10.1002/hep.23622
Van den Bossche, J., O’Neill, L. A., Menon, D. (2017). Macrophage immunometabolism: where are we (going)? Trends Immunol. 38 (6), 395–406. doi: 10.1016/j.it.2017.03.001
Vandivier, R. W., Henson, P. M., Douglas, I. S. (2006). Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129 (6), 1673–1682. doi: 10.1378/chest.129.6.1673
Vats, D., Mukundan, L., Odegaard, J. I., Zhang, L., Smith, K. L., Morel, C. R., et al. (2006). Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 4 (1), 13–24. doi: 10.1016/j.cmet.2006.05.011
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., Schwartz, S. M. (2000). Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20 (5), 1262–1275. doi: 10.1161/01.ATV.20.5.1262
Weiskirchen, R., Weiskirchen, S., Tacke, F. (2018). Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 7, 1–17. doi: 10.12688/f1000research.14841.1
Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., Zhang, Z. (2016). Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci. Rep. 6, 33386. doi: 10.1038/srep33386
Yamagata, M., Sanes, J. R., Weiner, J. A. (2003). Synaptic adhesion molecules. Curr. Opin. Cell Biol. 15 (5), 621–632. doi: 10.1016/S0955-0674(03)00107-8
Yin, J., McLachlan, C., Chaufour, X., McGuire, M. A., White, G., Turner, V., et al. (2000). Growth arrest-specific gene 6 expression in proliferating rabbit vascular smooth muscle cells in vitro and in vivo. Electrophoresis 21 (17), 3851–3856. doi: 10.1002/1522-2683(200011)21:17<3851::AID-ELPS3851>3.3.CO;2-H
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., et al. (2016). The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64 (5), 1577–1586. doi: 10.1002/hep.28785
Yu, S., Li, S., Henke, A., Muse, E. D., Cheng, B., Welzel, G., et al. (2016). Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases. FASEB J. 30 (7), 2570–2579. doi: 10.1096/fj.201600244R
Zhang, W., DeRyckere, D., Hunter, D., Liu, J., Stashko, M. A., Minson, K. A., et al. (2014). UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J. Med. Chem. 57 (16), 7031–7041. doi: 10.1021/jm500749d
Zhou, Y. Y., Zhou, X. D., Wu, S. J., Hu, X. Q., Tang, B., Poucke, S. V., et al. (2018). Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur. J. Gastroenterol. Hepatol. 30 (6), 631–636. doi: 10.1097/MEG.0000000000001075
Zizzo, G., Cohen, P. L. (2015). The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization. J. Inflamm. (Lond) 12, 36. doi: 10.1186/s12950-015-0081-4
Keywords: monocytes, macrophages, nonalcoholic fatty liver disease, MerTK, inflammation, atherosclerosis, drug targeting
Citation: Pastore M, Grimaudo S, Pipitone RM, Lori G, Raggi C, Petta S and Marra F (2019) Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. Front. Pharmacol. 10:604. doi: 10.3389/fphar.2019.00604
Received: 04 February 2019; Accepted: 14 May 2019;
Published: 29 May 2019.
Edited by:
Alfonso Pompella, University of Pisa, ItalyReviewed by:
Amedeo Lonardo, Azienda Ospedaliero-Universitaria di Modena, ItalyFrancesca Vinchi, Universität Heidelberg, Germany
Copyright © 2019 Pastore, Grimaudo, Pipitone, Lori, Raggi, Petta and Marra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chiara Raggi, chiara.raggi@unifi.it; Fabio Marra, fabio.marra@unifi.it